| scholarly article | Q13442814 |
| P50 | author | Timothy Synold | Q78536675 |
| P2093 | author name string | J Wright | |
| J Tuscano | |||
| P Frankel | |||
| S J Forman | |||
| C Karanes | |||
| M R O'Donnell | |||
| E M Newman | |||
| A S Stein | |||
| L Popplewell | |||
| J M Zain | |||
| B Pulone | |||
| A Rincon | |||
| M H Kirschbaum | |||
| P2860 | cites work | Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial | Q33364989 |
| Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development | Q33767883 | ||
| Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome | Q35007250 | ||
| Farnesyl transferase inhibitors in the treatment of breast cancer | Q35073354 | ||
| A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia | Q35628954 | ||
| Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines | Q37066258 | ||
| A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia | Q40030598 | ||
| A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. | Q40455631 | ||
| Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia | Q40543180 | ||
| Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? | Q41094489 | ||
| Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial | Q43615357 | ||
| Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer | Q44012109 | ||
| Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies | Q45166768 | ||
| Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer | Q73445688 | ||
| Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function | Q79157124 | ||
| Pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancer | Q80305635 | ||
| P433 | issue | 10 | |
| P921 | main subject | phase I clinical trial | Q5452194 |
| P304 | page(s) | 1543-1547 | |
| P577 | publication date | 2011-05-31 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia | |
| P478 | volume | 25 |
| Q34587614 | Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. |
| Q34052520 | Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia |
| Q38097334 | Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions |
| Q49501093 | Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. |
| Q47605042 | Prediction of Apparent Oral Clearance of Small-Molecule Inhibitors in Pediatric Patients |
| Q38058956 | Recent advances in protein prenyltransferases: substrate identification, regulation, and disease interventions |
| Q33614140 | Tipifarnib prevents development of hypoxia-induced pulmonary hypertension. |
| Q38386344 | Treatment of NRAS-mutant melanoma. |
| Q36373227 | Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib) |
Search more.